- Home
- SERA vs AARD Comparison
SERA vs AARD Comparison
Compare SERA & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SERA | AARD |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.2M | 165.8M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SERA | AARD |
|---|---|---|
| Price | $1.95 | $5.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | 30.9K | ★ 427.9K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $81,000.00 | N/A |
| Revenue This Year | $554.81 | N/A |
| Revenue Next Year | $517.27 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.19 | N/A |
| 52 Week Low | $1.56 | $3.35 |
| 52 Week High | $3.95 | $17.94 |
Technical Indicators
Market Signals| Indicator | SERA | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 50.79 | 56.39 |
| Support Level | $1.85 | $4.81 |
| Resistance Level | $2.03 | $6.27 |
| Average True Range (ATR) | 0.13 | 0.90 |
| MACD | 0.02 | 0.16 |
| Stochastic Oscillator | 60.53 | 48.85 |
Price Performance
Historical ComparisonAbout SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.